Who are Neurocrine Biosciences Inc's suppliers?

SentenceFor example, we depend on AbbVie for the manufacture and commercialization of ORILISSA and ORIAHNN and for the continued development of elagolix.

NBIX 10-Kaccession 0000914475-26-000007filed Feb 11 '26ABBV

KRCKilroy Realty Corp

Sentence12 Neurocrine Biosciences, Inc. (4) San Diego 16,365 299,064 2.1% 1.7% 2025 / 2029 / 2031 5.7

KRC 10-Kaccession 0001025996-25-000052filed Feb 13 '25KRC

MAZEMaze Therapeutics, Inc.

SentenceIn May 2024, we exclusively licensed our ATXN2 program to Neurocrine Biosciences, Inc.

MAZE 10-Kaccession 0001193125-26-122778filed Mar 25 '26MAZE

TAKTakeda Pharmaceutical Company Limited (Takeda)

SentenceTakeda Pharmaceutical Company Limited 37.5 7.5 —

NBIX 10-Kaccession 0000914475-26-000007filed Feb 11 '26TAK

VYGRVoyager Therapeutics, Inc.

SentenceFor 2024 compared to 2023, the decrease primarily reflected the payment of a $143.9 million upfront fee in 2023 pursuant to the expansion of our collaboration with Voyager.

NBIX 10-Kaccession 0000914475-26-000007filed Feb 11 '26VYGR

XENEXenon Pharmaceuticals Inc.

SentenceNBI‑921355 was in-licensed from Xenon Pharmaceuticals Inc. in 2019, and we retain global rights.

NBIX 10-Kaccession 0000914475-26-000007filed Feb 11 '26XENE

—Nxera Pharma UK Limited (Nxera)unlisted

SentenceNxera Pharma UK Limited $ 15.0 $ 50.0 $ —

NBIX 10-Kaccession 0000914475-26-000007filed Feb 11 '26

—Sentia Medical Sciences, Inc.unlisted

SentenceThis program represents the first biologic (peptide) to emerge from our internal discovery collaboration (with Sentia Medical Sciences, Inc.) on novel peptide CRF receptor antagonists, highlighting our expansion into biologics to complement our small-molecule portfolio.

NBIX 10-Kaccession 0000914475-26-000007filed Feb 11 '26

—Tanabe Pharma Corporation (formerly Mitsubishi Tanabe Pharma Corporation)unlisted

SentenceINGREZZA is marketed as DYSVAL ® (valbenazine) in Japan and REMLEAS ® (valbenazine) in other select Asian markets, where Tanabe Pharma Corporation (formerly Mitsubishi Tanabe Pharma Corporation) retains commercialization rights.

NBIX 10-Kaccession 0000914475-26-000007filed Feb 11 '26

customer

XENEXenon Pharmaceuticals Inc.

SentenceWe are dependent on our collaborators, including Neurocrine Biosciences, to fund and conduct the research and any clinical development of product candidates under our agreements with each of them, and for the successful regulatory approval, marketing and commercialization of one or more of such products or product candidates.

XENE 10-Kaccession 0001193125-26-076650filed Feb 26 '26XENE

Order: filed share, then A–Z, unlisted last

Methodology

ties · implied moves · holdersMethod

Ties Implied moves Holders

Dependency

Sources

Methodology

ties · implied moves · holdersMethod

Ties Implied moves Holders